KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.96

LRP1b Loss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized Trial.

Andrew J Armstrong, Hilary Dietz, David Balli, William J Geese, Chunzhe Duan, Yu-Han Hung, Virginia Ip, Gerald Li, Ryon P Graf, Neal Ready

Clin Cancer Res 31(24) 5198-5210

PMID41065506
PMCIDPMC12702137
DOI10.1158/1078-0432.CCR-25-0952
发表日期2025-10-09
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

PURPOSE: Low-density lipoprotein receptor-related protein 1b (LRP1b) is a cell surface receptor, commonly altered in many cancers and associated with improved responses, progression-free survival (PFS), and overall survival with immune checkpoint inhibition. EXPERIMENTAL DESIGN: LRP1b alterations were determined by whole-exome sequencing and associated with PFS and objective response rates in patients with non-small cell lung cancer (NSCLC) in a post hoc analysis of the randomized controlled phase III CheckMate-026 (CM026) trial (NCT02041533) examining chemotherapy compared with nivolumab, adjusting for tumor mutational burden (TMB) and clinical features. We separately evaluated a deidentified nationwide (US-based) NSCLC clinico-genomic database for associations of LRP1b alterations and PFS with anti-PD-1 immunotherapy. RESULTS: In the clinico-genomic database cohort of patients with NSCLC (N = 18,369), LRP1b mutations were positively associated with TP53/KRAS alterations and inversely with EGFR/RET/MET/ERBB2 alterations and significantly improved PFS with PD-1 inhibition (n = 1,569; adjusted HR, 0.86; P = 0.014). In CheckMate-026, patients with LRP1b alterations had a statistically significant improvement in objective response rate to nivolumab versus LRP1b wild-type patients (OR 3.5; 95% confidence interval, 1.71-7.13; P = 0.0006) but not with chemotherapy (OR 0.63; 95% confidence interval, 0.32-1.26; P = 0.19), adjusting for TMB, age, gender, histology, smoking, and performance status. LRP1b mutations were associated with improved PFS with nivolumab (HR, 0.66; P = 0.04) but not chemotherapy (HR, 1.26; P = 0.25), also maintained in multivariate and TMB-adjusted analyses. CONCLUSIONS: LRP1b mutations are a candidate predictive biomarker for immune checkpoint inhibition versus chemotherapy in NSCLC. Further mechanistic characterization of LRP1b and prospective validation are warranted and might enable future clinical use.

KM 提取结果

2 个 Figure · 6 个 KM 面板

进入结果中心
KM Figure4 个面板

Figure 2

Figure 2. Univariable associations of LRP1b and TMB in patients with NSCLC treated with single-agent anti-PD1 axis therapies. Outcome associations are visualized with Kaplan-Meier plots stratified by (A) any LRP1b alteration, (B) known or likely functional LRP1b status, (C) variant of unknown significance LRP1b status, and (D) by TMB10.

_A_

PFS

Figure 2 · Panel _A_

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel _A_ 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
_B_

PFS

Figure 2 · Panel _B_

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel _B_ 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
_C_

PFS

Figure 2 · Panel _C_

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel _C_ 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
_D_

PFS

Figure 2 · Panel _D_

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel _D_ 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure2 个面板

Figure 5

Figure 5. Evaluation of predictive value of LRPb1 mutation in CM026. (A) Univariate and multivariate analyses of ORR in nivolumab vs chemotherapy arms. (B-C) Kaplan-Meier plots of nivolumab vs chemotherapy by LRP1b status for the outcome of PFS. (D) Univariate and multivariate analyses of PFS in nivolumab vs chemotherapy arms. Multivariate analysis adjusts for age, sex, smoking history, performance status and histology.

B

PFS

Figure 5 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

PFS

Figure 5 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. ICI monotherapy cohort overview. Cohort selection diagram (A) and treatment diagram with index date (B).
非 KM Figure
Figure 3Figure 3. Multivariable associations of LRP1b and TMB in patients with NSCLC treated with single-agent anti-PD1 axis therapies. Relative hazards of progression are estimated with Cox PH models with variables shown. TMB and LRP1b are included as dichotomous variables in (A) and with additional stratifications in (B).
非 KM Figure
Figure 4Figure 4. Checkmate 026 Clinical Trial CONSORT diagram. a Samples were not available for various reasons, including but not limited to lack of patient pharmacogenetic consent, samples exhausted for PD-L1 testing, or poor tissue sampling b Samples dropout due to internal quality control failure such as too few sequence reads, and low or uneven target region coverage
非 KM Figure